physician fee schedules

At last.  Cue the Etta James music because the Centers for Medicare and Medicaid Services (CMS) released the final version of the Sunshine Act.  As of February 8, the Sunshine Act will be included in the Federal Register and will go into effect shortly thereafter....

By David Richardson, Research Team Leader The Office of the Inspector General at Health and Human Services (OIG) has been highly focused recently on tracking and publicizing pharmaceutical companies' payments to thought leader physicians and clinical...

By Elio Evangelista, Director of Research The United States is still waiting for the Centers for Medicare and Medicaid Services (CMS) to issue its final ruling on how it will implement the disclosure rules outlined in the Physician Payments Sunshine...

By Yanis Saradjian,Director of Consulting Our newly updated Fair-Market Value Benchmarking and Analysis service now provides medical, scientific and regulatory staff at life sciences companies with fair-market value benchmarks for thought leaders and influential...

Six Tips to Help Build the Ideal Thought Leader Database As the industry awaits the release of the delayed Sunshine Act guidelines, pharmaceutical and medical device companies are benefiting from the extra time by reviewing current physician payment reporting...

New study provides process for calculating compliant fair-market value payments Although 100 percent of drug companies compensate key opinion leaders (KOLs) for their method of travel, only 60 percent do so for any preliminary work. And as mandatory public...

By Elio Evangelista,Director of Research In about five weeks, pharmaceutical, biotechnology and medical device companies will have to start compiling and aggregating data on their physician expenditures to meet the requirements spelled out in the Physician...

By Ryan McGuire,Senior Research Analyst A study published in the British Medical Journal has received a lot of attention lately. It highlighted the prevalence of financial conflicts of interest (COI) for researchers sitting on 14 specific guideline-setting...

As compliance and medical affairs teams prepare for the Sunshine Act, they are relying less on exact compensation limits for key opinion leaders.  “KOL Fair-Market Value and Aggregate Spend: Documentation, Tracking and the Sunshine Act” found that only 35...

Just under one-third of drug manufacturers set a compensation limit on their European key opinion leaders to help drive compliant KOL interactions.  Executives interviewed for the study said that companies implement compensation limits to avoid overusing individual...